Since the founding of Gilead in 1987, we have focused on developing and delivering medications that advance the treatment of life-threatening diseases. The commercial success of our products provides us with the resources to generate new clinical data defining their profiles and supports our development of new therapeutic advancements. As we bring new products into clinical development, our goal remains the same - to discover, develop and commercialize therapeutics that advance patient care.

 

  • 2014
    Zydelig®
    July 23, 2014: Zydelig® approved
  • 2013
    Sovaldi®
    December 6, 2013: Sovaldi® approved
  • 2012
    Stribild®
    August 27, 2012: Stribild approved
    Truvada® (for PrEP)
    July 16, 2012: Truvada for PrEP approved
  • 2011
    Complera®
    August 10, 2011: Complera approved
  • 2010
    Cayston®
    February 22, 2010: Cayston approved
  • 2009
  • 2008
    Lexiscan®
    April 10, 2008: Lexiscan approved
    Viread® (for HBV)
    August 11, 2008: Viread for hepatitis B approved
  • 2007
    Letairis®
    June 15, 2007: Letairis approved
  • 2006
    Atripla®
    July 12, 2006: Atripla approved
    Ranexa®
    January 31, 2006: Ranexa approved
  • 2005
  • 2004
    Macugen®
    December 20, 2004: Macugen approved
    Truvada® (for HIV)
    August 2, 2004: Truvada approved
  • 2003
    Emtriva®
    July 2, 2003: Emtriva approved
  • 2002
    Hepsera®
    September 20, 2002: Hepsera approved
  • 2001
    Viread® (for HIV)
    October 26, 2001: Viread approved
  • 2000
  • 1999
    Tamiflu®
    October 27, 1999: Tamiflu approved
  • 1996
    Vistide®
    June 27, 1996: Vistide approved
  • 1990
    AmBisome®
    1990: AmBisome approved (in Europe; U.S. approval in 1997)
  • 1987
    Gilead Founded